drugset / Trial / NCT02218073

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

NCT02218073

Phase 1 Completed 8 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the absolute bioavailability (the extent to which a drug or other substance becomes available to the body) of JNJ-42756493 following a single 10 milligram (mg) dose as an oral solution administered in combination with a single intravenous administration of a microdose (100 microgram \[mcg\]) of JNJ-61818549 and to evaluate the relative bioavailability of 10 mg JNJ-42756493 following an oral solution (reference) and a tablet (test) formulation in a crossover (method used to switch subjects from one study group to another in a clinical trial) design in healthy participants.

Timeline

Start
2014-10
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Erdafitinib Small molecule 10 mg Oral
Subject JNJ-61818549 Unknown 100 ug Intravenous

Indications

No indication recorded.